The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04276298




Registration number
NCT04276298
Ethics application status
Date submitted
17/02/2020
Date registered
19/02/2020

Titles & IDs
Public title
Topical Analgesia Post-Haemorrhoidectomy
Scientific title
A Prospective, Multicentre, Double-Blinded Randomised Controlled Trial Comparing Topical Metronidazole, Diltiazem and Lidocaine on Post-Operative Pain Following Excisional Haemorrhoidectomy
Secondary ID [1] 0 0
RCT Haemorrhoidectomy
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemorrhoid Pain 0 0
Hemorrhoids 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Metronidazole cream
Treatment: Drugs - Metronidazole and Diltiazem cream
Treatment: Drugs - Metronidazole and Lidocaine cream
Treatment: Drugs - Metronidazole, Diltiazem and Lidocaine cream

Active comparator: Metronidazole - Group A receiving 10% metronidazole cream

Active comparator: Metronidazole + Diltiazem - Metronidazole 10% + Diltiazem 2%

Active comparator: Metronidazole + Lignocaine - Metronidazole 10% + Lignocaine 4%

Active comparator: Metronidazole + Diltiazem + Lignocaine - Metronidazole 10% + Diltiazem 2% + Lignocaine 4%


Treatment: Drugs: Metronidazole cream
10% metronidazole applied rectally

Treatment: Drugs: Metronidazole and Diltiazem cream
Combination Metronidazole and Diltiazem applied rectally

Treatment: Drugs: Metronidazole and Lidocaine cream
Combination metronidazole and lignocaine applied rectally

Treatment: Drugs: Metronidazole, Diltiazem and Lidocaine cream
Combination of all active agents tested applied rectally

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pain scores
Timepoint [1] 0 0
7 days
Primary outcome [2] 0 0
Amount of analgesic use
Timepoint [2] 0 0
7 days
Secondary outcome [1] 0 0
Return to work
Timepoint [1] 0 0
14 days
Secondary outcome [2] 0 0
Pain on bowel motion: Visual Analog Scale
Timepoint [2] 0 0
7 days
Secondary outcome [3] 0 0
Complications
Timepoint [3] 0 0
30 days
Secondary outcome [4] 0 0
Re-admission
Timepoint [4] 0 0
30 days
Secondary outcome [5] 0 0
Repeat Prescription
Timepoint [5] 0 0
30 days

Eligibility
Key inclusion criteria
* Age =16
* All patients undergoing excisional haemorrhoidectomy
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Age <16,
* history of chronic pain,
* drug allergy or idiosyncracies to any actives or excipients in
* cream,
* breastfeeding,
* any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including:
* sick sinus syndrome,
* atrioventricular block,
* hypotension,
* heart failure and bradycardia.
* concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem.
* patients already taking diltiazem.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Factorial
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Other
Name
University of Auckland, New Zealand
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Andrew G Hill, MBChB, MD, EdD, FRACS, FACS
Address 0 0
Counties Manukau Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Will be shared when results become available.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF)
When will data be available (start and end dates)?
When results are available for 12 months
Available to whom?
email request
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.